Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023

Raymond Schiffelers's Biography

Raymond Schiffelers, Professor of Nanomedicine, University Medical Center Utrecht

Raymond Schiffelers studied Bio-Pharmaceutical Sciences at Leiden University (1990-1995). After an industrial traineeship at SmithKline Beecham Pharmaceuticals (UK) he did his PhD in medical microbiology at Erasmus University Rotterdam on liposomal targeting of antimicrobial agents (1996-2001). Subsequently he became post-doc at Utrecht University working on liposomes targeting tumor vasculature. In 2002-2003, at Intradigm Co (USA) he expanded his tumor vasculature-targeting work with polymers for delivery of siRNA. After his return to Utrecht University he became assistant and then associate professor. He received an ERC Consolidator Grant in 2010 to investigate extracellular vesicles as biological drug delivery systems. After he moved to University Medical Center Utrecht in 2011 he became professor of nanomedicine working on bio-inspired and synthetic drug delivery systems. He coordinates two H2020 projects on this topic, B-SMART and EXPERT, is editor for the International Journal of Pharmaceutics, Journal of Controlled Release and Journal of Extracellular Vesicles, and is founder of EXCYTEX-an extracellular vesicle-based company. Since 2021 he also works part-time for Nanocell Therapeutics as VP Preclinical R&D and is president of the ETPN.

Raymond Schiffelers Image

Synthetic Lipid Nanocarriers: From Liposomes to Lipid Nanoparticles

Tuesday, 14 November 2023 at 09:00

Add to Calendar ▼2023-11-14 09:00:002023-11-14 10:00:00Europe/LondonSynthetic Lipid Nanocarriers: From Liposomes to Lipid NanoparticlesExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The

2023 marks the sixtieth birthday of ‘liposomes’. These structures were shown to spontaneously form when amphiphilic lipids were brought in an aqueous environment. In the next decades, many lessons were learned on the biomedical applications of liposomes on the effects of liposome size and surface charge, on steric stabilization and lipid composition, on targeting and immune evasion. Tens of liposome-based products are currently marketed or in advanced stages of clinical development. The most recent addition to the clinically used nanocarriers are the lipid nanoparticles for the delivery of nucleic acids. Building on the foundations of liposomes, these newest type of particles have been successfully used in the siRNA-product patisiran. This recipe also formed the basis for the mRNA COVID-vaccines. These successes paved the way for many new applications where synthetic lipid nanoparticles enable new nucleic acid modalities for advanced therapeutic interventions.

Add to Calendar ▼2023-11-13 00:00:002023-11-14 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023Extracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The